1.
Evolving concepts in the treatment of relapsing multiple sclerosis
by Comi, Giancarlo, Prof
The Lancet (British edition), 2016, Vol.389 (10076), p.1347-1356
2.
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
by Coles, Alasdair J, Dr
The Lancet (British edition), 2012, Vol.380 (9856), p.1829-1839
3.
Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
by Keystone, Edward C
Annals of the rheumatic diseases, 2015, Vol.74 (2), p.333-340
4.
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
by Lublin, Fred, Prof
The Lancet (British edition), 2016, Vol.387 (10023), p.1075-1084
5.
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)
by Mease, P J
Annals of the rheumatic diseases, 2014, Vol.73 (1), p.48-55
6.
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
by Walter, Steffen
Nature medicine, 2012, Vol.18 (8), p.1254-1261
7.
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Ph...
by Landewé, R
Annals of the rheumatic diseases, 2014, Vol.73 (1), p.39-47
8.
A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modif...
by Burmester, Gerd R
Annals of the rheumatic diseases, 2014, Vol.73 (1), p.69-74
9.
Systematic review with meta‐analysis: the efficacy of a second anti‐TNF in patients with inflammatory bowel disease whose previous anti‐TNF treatment has failed
by Gisbert, J. P.
Alimentary pharmacology & therapeutics, 2015, Vol.41 (7), p.613-623
10.
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a r...
by Hermine, Olivier, Prof
The Lancet (British edition), 2016, Vol.388 (10044), p.565-575
11.
Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease – a SONIC post hoc analysis
by Colombel, J.‐F.
Alimentary pharmacology & therapeutics, 2015, Vol.41 (8), p.734-746
12.
Aerosol drug delivery: developments in device design and clinical use
by Dolovich, Myrna B, Prof
The Lancet (British edition), 2011, Vol.377 (9770), p.1032-1045
13.
Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study
by Danese, Silvio
Gut, 2015, Vol.64 (2), p.243-249
14.
Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-control...
by Wallace, Daniel J
Annals of the rheumatic diseases, 2014, Vol.73 (1), p.183-190
15.
Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial
by Budde, Klemens, Prof
The Lancet (British edition), 2011, Vol.377 (9768), p.837-847
16.
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease
by Vermeire, Severine
Gut, 2007, Vol.56 (9), p.1226-1231
17.
Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, pha...
by Papp, Kim, Dr
The Lancet (British edition), 2017, Vol.390 (10089), p.40-49
18.
Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial
by Griffiths, Paul D, Prof
The Lancet (British edition), 2011, Vol.377 (9773), p.1256-1263
19.
Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis
by Siontis, George C M, MD
The Lancet (British edition), 2015, Vol.386 (9994), p.655-664
20.
Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials
by Cassese, Salvatore, Dr
The Lancet (British edition), 2016, Vol.387 (10018), p.537-544
